Pfizer Acquires a Stem-Cell Therapy

Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in stem cells.

Pfizer will have the rights to develop Athersys’s cells to treat inflammatory bowel disease, the companies are expected to announce on Monday. It will pay Athersys $6 million initially and up to $105 million in the future.

read more:

Incoming search terms:

stemgenex complaints, stemgenex reviews, stemgenex cost, Athersys Fraud, is stemgenex legit, stemgenex review, reviews of stemgenex, stemgenex testimonials, Pfizer cell therapy, genex stem cell fraud, stemedix reviews, stemedix complaints against, stemedix or stemgenics which better, pfizer stem cell, Stemgenex stock price?, stemgenex reviews on stroke treatmen, stemgenex reviews fraud, reviews stemedix, stem genex ratings, stemgenex patient review, Waisman athersys.

2 thoughts on “Pfizer Acquires a Stem-Cell Therapy”

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>